Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTalha MunirAVAndrea VisentinLMLeyla Mohseninejad

Discussion

Loading...

Member takes

Overview

NNT model estimates 20 cardiac deaths avoided in 2L CLL patients with zanubrutinib instead of ibrutinib, indicating treatment implications.

Key Points

  • To estimate cardiac deaths associated with ibrutinib versus zanubrutinib in chronic lymphocytic leukemia patients in Europe.
  • Utilized a number needed to treat (NNT) model for estimating cardiac deaths.
  • Analyzed data from ALPINE and SEQUOIA trials for 2L and 1L CLL settings, respectively.
  • Employed real-world data from the IQVIA Oncology Dynamics database.
  • Estimated 1,555 2L+ CLL patients started on ibrutinib treatment.
  • 20 cardiac deaths may have been avoided with zanubrutinib instead of ibrutinib in 2L+ setting.
  • 19 cardiac deaths could be avoided in the 1L setting with treatment switch.

Cite This Study

Munir et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1c8https://doi.org/10.1182/blood-2025-8033
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States2025
  2. 2Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies2025
  3. 3Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  4. 4Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis2025
  5. 5Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study2025 · 5 citations